Cuscuta Chinensis (Tu Si Zi)

PreclinicalSmall molecule

Cuscuta Chinensis (Tu Si Zi) is one of 31 small molecule programs targeting Dysmenorrhea. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DysmenorrheaActive, not recruiting

DysmenorrheaPreclinical

Active, not recruiting

Competition

Competitive Landscape

85 competitors in Dysmenorrhea

#DrugCompanyPhaseTrials

Arcoxia

Novartis

Phase 3

2 2

Advil

KKenvue Brands

Phase 3

9 3

Cataflam

Novartis

Phase 3

1 4

Sumatriptan Succinate

GSK

Phase 3

1 5

Comparator: Statins

Merck & Co.

Phase 3

1 6

Pelubiprofen

Daewon Pharmaceutical Co., Ltd.

Phase 3

1 7

Anjeso

Boehringer Ingelheim

Phase 2

2 8

Xeomin

MMerz Therapeutics GmbH

Xylocaine

1 10

Implanon

OOrganon and Co

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dysmenorrhea1 trial

A Preliminary Study on the Efficacy of Danggui Shaoyao San and Cuscuta Chinensis in Patients with Primary Dysmenorrhea

Not yet recruiting·TTaichung Tzu Chi Hospital·N/A·NCT06730282·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cuscuta Chinensis (Tu Si Zi). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cuscuta Chinensis (Tu Si Zi) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cuscuta Chinensis (Tu Si Zi). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taichung Tzu Chi Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTaichung Tzu Chi Hospital

Cuscuta Chinensis (Tu Si Zi)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dysmenorrhea1 trial

References

Drug Info

Quick Facts

Related News